Regulatory Coordinator

Full course · Protocol Amendment Management

Managing the gap period: what happens when participants arrive between amendment approval and reconsent completion — Protocol Amendment Management

Managing the gap period: what happens when participants arrive between amendment approval and reconsent completion

Teaches RCs to manage the operationally complex window between IRB approval of an amended consent form and completion of reconsent for all affected participants, including visit conduct decision trees, scenario-based response protocols, and documentation requirements.

25 min

The amendment is approved. The participant is here. The consent form is not signed.

The IRB approved Amendment 3 on Monday morning. By Monday afternoon, the coordinator had updated the regulatory binder, filed the approval letter, and begun building the reconsent schedule using the tracking system from the previous lesson. Forty-eight participants need reconsent. The team estimated two weeks to reach everyone -- a reasonable timeline, given the visit schedule and the site's capacity for reconsent conversations.

It is now Wednesday. A participant has arrived for a scheduled visit. This visit includes standard labs, a joint assessment, and -- per the amendment just approved 48 hours ago -- a new biomarker blood draw that was not part of the original protocol. The participant has not been reconsented. The new consent form is printed and ready, but the participant walked through the door expecting a routine visit, not a consent conversation about changes to the study.

What happens now?

This is the gap period: the window between the moment an amended consent form receives IRB approval and the moment every affected participant has been reconsented. It is, in my experience, the most operationally treacherous phase of any amendment cycle. Not because the regulatory requirements are ambiguous -- they are actually quite clear -- but because the gap period is where regulatory obligations collide with clinical reality. Participants do not pause their disease progression while the site completes administrative processes. They arrive when their visit schedule says to arrive. They experience adverse events on their own timeline. They call the site with questions that now have different answers than they did last week.

The previous lessons in this module built the infrastructure: determining when reconsent is required, designing the reconsent plan, and deploying the tracking system that monitors completion. This lesson addresses what the RC must build to manage the interval before that tracking system shows 100% -- the procedures, decision frameworks, and documentation standards that govern site operations during the gap.

What you will learn3 objectives

By the end of this lesson, you will be able to:

Evaluate the regulatory requirements governing the gap period between amendment approval and reconsent completion, including what study activities may proceed, what activities must wait, and how to document the rationale for each decision per ICH E6(R3) Sections 2.5.2 and 2.8.2
Design gap period management procedures -- including visit conduct decision trees, documentation templates, and team communication protocols -- that the site can apply consistently across studies
Analyze the distinct gap period scenarios (participant arrives for a routine visit before reconsent, participant experiences an adverse event during the gap period, participant contacts the site between visits) and determine the appropriate operational response for each

Progress saves itself — finish reading and this lesson completes

Continue with the Regulatory Coordinator track

The amendment is approved. The participant is here. The consent form is not signed.